Category survey

Development of Novel Machine Learning methodologies for early Parkinson’s disease diagnosis from multi-modal MRI Investments < €500k Luxembourg 2016    

Genome-scale exploration of flux distributions for dopaminergic neurons in Parkinson’s disease Investments < €500k Luxembourg 2016    

Development and validation of a human three-dimensional in vitro midbrain model Investments < €500k Luxembourg 2016    

Patient-specific control of movement disorders in Parkinson’s disease by using deep brain stimulation Investments < €500k Luxembourg 2016    

Microscopic image analysis of the relationship between electrophysiological energy cost and dopaminergic neuronal degeneration in vitro. Investments < €500k Luxembourg 2016    

Cell-type specific changes in gene-networks in the human brain: towards a selective Alzheimer therapeutic target Investments < €500k Netherlands 2016    

Automated Multimodality Image-based Classifiers for Early Detection of Alzheimer’s Disease Investments < €500k Netherlands 2016    

Capturing changes in cognition: developing a measure for progression in dementia Investments < €500k Netherlands 2016    

PRODIA: Development of biomarkers enabling early and accurate differential diagnosis of dementia Investments < €500k Netherlands 2016    

Prevalence, characteristics and quality of life of nursing home patients with dementia with (very) severe or extreme neuropsychiatric symptoms (the WAALBED-III-study) Investments < €500k Netherlands 2016    

Functional brain connectivity: a new imaging marker for preclinical dementia? Investments < €500k Netherlands 2016    

Paracetamol to enhance quality of life and daily function and to decrease care dependency in advanced dementia: A randomized, double-blind, placebo-controlled crossover trial in long-term care facilities. Investments < €500k Netherlands 2016    

Developing an early reliable blood-derived biomarker of cognitive deterioration Investments < €500k Ireland 2016    

D-activating Decline’: Exploring the combined effects of exercise and vitamin D3 supplementation on cognitive function in healthy older adults. Investments < €500k Ireland 2016    

Adult stem cells as vehicles for delivery of neurotrophic factors to the degenerating brain Investments < €500k Ireland 2016    

Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis Investments < €500k Ireland 2016    

Harnessing Adult Stem Cells for Neurotrophin Delivery to the Degenerating Brain Investments < €500k Ireland 2016    

microRNA as novel therapeutic targets and disease biomarkers in Alzheimer’s Disease, Frontotemporal dementia and Anyotrophic lateral sclerosis (NEURO-MIR) Investments < €500k Ireland 2016    

H2020 Catalyst Award: Targeting glial plasticity to alleviate age-related loss of neuronal function in Alzheimer’s disease Investments < €500k Ireland 2016    

Elucidating the mechanism linking Protein Aggregation Disease to DNA Damage Response Investments < €500k Israel 2016    

ADAM10 nella Malattia di Huntington: studio molecolare e funzionale della sinapsi. ADAM10 in Huntington’s disease: molecular and functional study of the synapse Investments < €500k Italy 2016    

DJ-1 Linked Neurodegeneration Pathways in New Mouse Models of Parkinson’s Disease Investments < €500k Luxembourg 2016    

Analysis of the impact of ROS in networks describing neurodegenerative diseases Investments < €500k Luxembourg 2016    

Personalized Computer Aided Navigation for Stereotactic Surgery Investments < €500k Luxembourg 2016    

Exploring Parkinson’s Disease Inhibitor Efficacy on a Non-dopaminergic Target Investments < €500k Luxembourg 2016    

Generation and characterization of a human dopamine producing cell system Investments < €500k Luxembourg 2016    

Utilization of TALEN technology to investigate the microRNA dependence of PD-associated defects in neural stem cell activity. Investments < €500k Luxembourg 2016    

Analysis of mitophagy in neural stem cells carrying Parkinson’s disease associated mutations in LRRK2. Investments < €500k Luxembourg 2016    

Patient-specific Segmentation of Cerebral Structures for Deep Brain Stimulation Investments < €500k Luxembourg 2016    

Reconstruction and computational modelling of dopaminergic neuronal metabolism Investments < €500k Luxembourg 2016    

Energy Metabolism of Dopaminergic Neurons in Microfluidic Cell Culture Investments < €500k Luxembourg 2016    

Establishment of a laboratory for biomarker research of the central nervous system Investments < €500k Hungary 2016    

SOPHIA: Sampling and biomarker optimisation and harmonisation in ALS and other motor neuro diseases Investments < €500k Ireland 2016    

Taking the Stress out of Dementia Caregiving Investments < €500k Ireland 2016    

Dementia and Neurodegeneration Network Ireland (DNNI) Investments < €500k Ireland 2016    

Behavioural Changes in ALS : What Families and Healthcare Professionals Need to Know Investments < €500k Ireland 2016    

Harnessing the anti-inflammatory potential of cannabinoid CB2 receptors for disease modification in Parkinson’s disease Investments < €500k Ireland 2016    

Validation of the Profile for Communication Abilities in Dementia (P-CAD) Investments < €500k Ireland 2016    

Examining the effects of S1P receptor drugs in Alzheimer’s disease Investments < €500k Ireland 2016    

Angiogenin as a therapeutic for the treatment of ALS Investments < €500k Ireland 2016    

Novel biomarkers of ALS subphenotypes using advanced imaging and spectral EEG technology Investments < €500k Ireland 2016    

Botulinum toxin for sialorrhea in people with Parkinson’s disease Investments < €500k Ireland 2016    

Taking the Stress out of Dementia Caregiving Investments < €500k Ireland 2016    

A National Dementia Registry for Ireland: A feasbility analysis Investments < €500k Ireland 2016    

Putting the brakes on Alzheimer’s disease: Exercise and its effects on cognitive decline, neurogenesis and inflammation in the APP/PS-1 mouse Investments < €500k Ireland 2016    

Exploring personhood in dementia and its importance for care relationships, service delivery and regulatory instruments. Investments < €500k Ireland 2016    

Personhood in dementia: A participatory-action research investigation of the value of agency in community Investments < €500k Ireland 2016    

Gene-environment interactions as an approach to modelling Parkinson’s disease Investments < €500k Ireland 2016    

Investigation of mechanisms by which PINK1 protects against Parkinson’s disease: to develop better biomarkers and treatment targets for the disease. Investments < €500k Ireland 2016    

Molecular determinants of CAG repeat expansions in Huntington’s disease Investments < €500k Ireland 2016